HealthBeacon plc (HBCNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HealthBeacon plc (HBCNF) trades at $0.50 with AI Score 44/100 (Grade C). HealthBeacon plc develops and commercializes digital therapeutic solutions for at-home injectable medication management. Market cap: $8.44M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for HBCNF: HBCNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HBCNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HBCNF: the 1 perspectives are evenly split.
How is this calculated? →HealthBeacon plc (HBCNF) Healthcare & Pipeline Overview
HealthBeacon plc offers a digital therapeutics platform for managing injectable medications at home, leveraging technology to improve patient adherence and outcomes. The company operates in Europe, the United States, and Ireland, providing medication management, sharps disposal, and AI-driven data analytics within the healthcare information services sector.
What Is the Investment Thesis for HBCNF?
HealthBeacon plc presents a notable research candidate within the growing digital therapeutics market. The company's focus on improving medication adherence for injectable medications addresses a significant unmet need. Key value drivers include expansion into new geographic markets and partnerships with pharmaceutical companies and healthcare providers. The company's negative P/E ratio of -0.55 and a negative profit margin of -588.6% indicate that the company is not currently profitable. The company's low gross margin of 6.0% suggests challenges in achieving profitability. Upcoming catalysts include potential regulatory approvals and new product launches. The company's beta of -0.29 suggests lower volatility than the market.
Based on FMP financials and quantitative analysis
HBCNF Key Highlights
- HealthBeacon plc operates in the digital therapeutics market, focusing on medication adherence for injectable medications.
- The company's injection care management system includes medication reminders, sharps disposal, and data analytics.
- HealthBeacon's solutions are available in Europe, the United States, and Ireland.
- The company's market capitalization is approximately $0.01 billion.
- HealthBeacon's gross margin is 6.0%.
Who Are HBCNF's Competitors?
HBCNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CDXFF Cloud DX Inc. | $0.09 | +12.50% | $9.75M | 54 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| DOCRF CloudMD Software & Services Inc. | $0.02 | -19.29% | $6.25M | 38 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HBCNF's Key Strengths?
- Proprietary technology for medication adherence.
- Focus on injectable medications, a growing market.
- Partnerships with pharmaceutical companies.
- AI-driven data analytics for personalized interventions.
What Are HBCNF's Weaknesses?
- Limited financial resources.
- Small market capitalization.
- Negative profitability.
- Reliance on partnerships for growth.
What Could Drive HBCNF Stock Higher?
- Potential regulatory approvals for new products and services.
- Expansion into new geographic markets.
- Partnerships with pharmaceutical companies to integrate its solutions into their drug delivery programs.
- Development of new products and services to address other aspects of medication management.
- Integration with electronic health records (EHRs) to provide healthcare providers with a more complete view of their patients' medication adherence.
What Are the Key Risks for HBCNF?
- Negative return on equity (-56.5%) — the business is not currently generating profit on shareholder capital.
- Competition from established healthcare companies.
- Regulatory hurdles for digital therapeutics.
- Data privacy and security concerns.
- Reimbursement challenges for digital health solutions.
- Limited financial resources may hinder growth initiatives.
What Are the Growth Opportunities for HBCNF?
- Expansion into new geographic markets: HealthBeacon has the opportunity to expand its presence in Europe and the United States, as well as enter new markets in Asia and Latin America. The global market for digital therapeutics is projected to reach $9.6 billion by 2027, providing a significant growth opportunity for the company. Timeline: Ongoing.
- Partnerships with pharmaceutical companies: HealthBeacon can partner with pharmaceutical companies to integrate its medication adherence solutions into their drug delivery programs. This can help pharmaceutical companies improve patient outcomes and increase sales. The pharmaceutical industry spends billions of dollars annually on patient support programs, creating a potential revenue stream for HealthBeacon. Timeline: Ongoing.
- Development of new products and services: HealthBeacon can develop new products and services to address other aspects of medication management, such as medication reconciliation and drug interactions. The market for medication management solutions is growing rapidly, driven by the increasing complexity of medication regimens. Timeline: Ongoing.
- Integration with electronic health records (EHRs): HealthBeacon can integrate its medication adherence data with EHRs to provide healthcare providers with a more complete view of their patients' medication adherence. This can help healthcare providers make more informed treatment decisions. The adoption of EHRs is increasing rapidly, creating a growing demand for integrated medication adherence solutions. Timeline: Ongoing.
- Leveraging AI and machine learning: HealthBeacon can leverage AI and machine learning to personalize medication adherence interventions and predict which patients are at risk of non-adherence. This can help healthcare providers target their interventions more effectively. The use of AI and machine learning in healthcare is growing rapidly, creating new opportunities for innovation. Timeline: Ongoing.
What Opportunities Does HBCNF Have?
- Expansion into new geographic markets.
- Development of new products and services.
- Integration with electronic health records.
- Increasing adoption of digital therapeutics.
What Threats Does HBCNF Face?
- Competition from established healthcare companies.
- Regulatory hurdles for digital therapeutics.
- Data privacy and security concerns.
- Reimbursement challenges for digital health solutions.
What Are HBCNF's Competitive Advantages?
- Proprietary technology: HealthBeacon's injection care management system is protected by patents and trade secrets.
- Data analytics: HealthBeacon's AI-driven data analytics provide valuable insights into patient adherence.
- Partnerships: HealthBeacon has established partnerships with pharmaceutical companies and healthcare providers.
What Does HBCNF Do?
HealthBeacon plc, established in 2013 and headquartered in Dublin, Ireland, is a digital therapeutics company focused on improving medication adherence for patients managing injectable medications at home. The company's core product is an injection care management system that combines technology and services to support patients throughout their treatment journey. This system provides medication management reminders, safe sharps disposal devices, educational tools, and AI-driven data analytics to track adherence and persistence. HealthBeacon's solutions are available in Europe, the United States, and Ireland. The company sells and leases its medical adherence technology devices and injection care management systems to healthcare providers and patients directly. By addressing the challenges of medication adherence, HealthBeacon aims to improve patient outcomes and reduce healthcare costs associated with non-adherence.
What Products and Services Does HBCNF Offer?
- Develops digital therapeutic solutions for managing injectable medications at home.
- Provides medication management reminders to patients.
- Offers safe and sustainable sharps disposal devices.
- Provides educational tools to patients.
- Utilizes AI-driven data analytics to track medication adherence.
- Sells and leases medical adherence technology devices.
- Offers injection care management systems.
How Does HBCNF Make Money?
- Sells and leases medical adherence technology devices to healthcare providers and patients.
- Generates revenue from subscriptions to its injection care management system.
- Partners with pharmaceutical companies to integrate its solutions into their drug delivery programs.
What Industry Does HBCNF Operate In?
The healthcare information services industry is experiencing rapid growth, driven by the increasing adoption of digital health solutions and the need for improved patient outcomes. The market for digital therapeutics is projected to reach billions of dollars in the coming years. HealthBeacon plc operates in this dynamic landscape, competing with companies offering medication adherence solutions and remote patient monitoring technologies. Competitors include BNOEF (Biofrontera Inc), CDXFF (CareDx Inc), CRBKF (Cornerstone Bank), DOCRF (Doximity Inc), and FLWPF (Welltower Inc). HealthBeacon's focus on injectable medications differentiates it from some competitors.
Who Are HBCNF's Key Customers?
- Patients who require injectable medications for chronic conditions.
- Healthcare providers who prescribe injectable medications.
- Pharmaceutical companies that manufacture injectable medications.
HBCNF Valuation & Market Position
With a $8.44M market cap, HealthBeacon plc sits in the micro-cap segment of the market. Relative to its peer group, HBCNF's quantitative score of 44/100 is below the peer average of 59/100.
ROE -57%Key Financial Metrics
Return on equity for HealthBeacon plc stands at -56.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -53.1%, showing how much profit it generates from its asset base. A current ratio of 2.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -178.7%, the inverse of the P/E and a quick read on earnings relative to price.
HBCNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary technology for medication adherence.
- Focus on injectable medications, a growing market.
- Partnerships with pharmaceutical companies.
- AI-driven data analytics for personalized interventions.
Bear Case
- Limited financial resources.
- Small market capitalization.
- Negative profitability.
- Reliance on partnerships for growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HBCNF Latest News
No recent news available for HBCNF.
HBCNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HBCNF.
Price Targets
Wall Street price target analysis for HBCNF.
HBCNF MoonshotScore
What does this score mean?
The MoonshotScore rates HBCNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kieran Daly
CEO
Kieran Daly is the Chief Executive Officer of HealthBeacon plc. His background includes experience in the healthcare and technology sectors. He has held leadership positions in various companies, focusing on commercial strategy and business development. Daly's expertise lies in driving growth and innovation in the healthcare industry. He is responsible for leading HealthBeacon's strategic direction and execution.
Track Record: Under Kieran Daly's leadership, HealthBeacon plc has focused on expanding its market presence in Europe and the United States. He has overseen the development and launch of new products and services, including the integration of AI-driven data analytics into the company's injection care management system. Daly has also been instrumental in forging partnerships with pharmaceutical companies and healthcare providers.
HBCNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that HealthBeacon plc may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial information available to investors, and trading activity may be sporadic. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure: The lack of comprehensive financial information increases investment risk.
- Low liquidity: Difficulty in buying or selling shares can lead to significant price fluctuations.
- Higher price volatility: The combination of low liquidity and limited information can result in increased price volatility.
- Potential for fraud or manipulation: The OTC market is subject to less regulatory oversight than major exchanges, increasing the risk of fraudulent or manipulative activities.
- Going concern risk: Companies on the OTC Other tier may face financial difficulties and have a higher risk of going out of business.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and any outstanding debt.
- Check for any regulatory filings or legal proceedings.
- Consult with a qualified financial advisor.
- Company is registered and incorporated in Ireland.
- HealthBeacon has partnerships with established pharmaceutical companies.
- The company has a functional website and actively promotes its products and services.
- HealthBeacon's products address a clear need in the healthcare market.
- Company has been in operation since 2013.
HealthBeacon plc Healthcare Stock: Key Questions Answered
What does HealthBeacon plc do?
HealthBeacon plc is a digital therapeutics company specializing in medication adherence solutions for patients using injectable medications at home. The company's core offering is an injection care management system that combines technology and services to improve patient outcomes. This system includes medication reminders, safe sharps disposal, educational resources, and AI-driven data analytics to monitor adherence and persistence. HealthBeacon generates revenue through the sale and lease of its devices and subscription services, targeting patients, healthcare providers, and pharmaceutical companies.
What do analysts say about HBCNF stock?
As of 2026-03-18, there is no readily available analyst consensus on HBCNF stock due to its OTC listing and limited coverage. Key valuation metrics such as P/E ratio (-0.55) and profit margin (-588.6%) suggest the company is not currently profitable. Growth considerations include the company's ability to expand into new markets, secure partnerships, and develop new products. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for HBCNF?
The main risks for HealthBeacon plc include competition from established healthcare companies, regulatory hurdles for digital therapeutics, data privacy and security concerns, and reimbursement challenges for digital health solutions. Additionally, the company's limited financial resources and OTC listing present additional risks. Investors should also consider the potential for product obsolescence and the need for continuous innovation to maintain a competitive advantage. The company's low gross margin of 6.0% indicates challenges in achieving profitability.
How does HealthBeacon plc manage patent expiration risks?
HealthBeacon plc mitigates patent expiration risks by continuously innovating and developing new features and products for its injection care management system. The company also focuses on building strong relationships with pharmaceutical companies and healthcare providers, which can provide a competitive advantage even after patents expire. Additionally, HealthBeacon may pursue strategies such as extending patent protection through secondary patents or developing proprietary know-how that is difficult to replicate.
What is HealthBeacon plc's strategy for expanding its market share in the competitive digital therapeutics market?
HealthBeacon plc's strategy for expanding its market share in the digital therapeutics market involves several key initiatives. These include focusing on specific therapeutic areas, such as diabetes and autoimmune diseases, where injectable medications are commonly used. The company also aims to differentiate itself through its AI-driven data analytics and personalized medication adherence interventions. Furthermore, HealthBeacon seeks to establish strategic partnerships with pharmaceutical companies and healthcare providers to expand its reach and access new markets. The company's goal is to become a leading provider of medication adherence solutions for injectable medications.
What are the key factors to evaluate for HBCNF?
HealthBeacon plc (HBCNF) holds an AI score of 44/100 (low). Not financial advice.
How frequently does HBCNF data refresh on this page?
HBCNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HBCNF's recent stock price performance?
HealthBeacon plc (HBCNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology for medication adherence. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than major exchange data.
- AI analysis is pending and may provide additional insights in the future.